Group 1 - The core focus of the news is the progress of Ascletis Pharma's oral small molecule GLP-1 receptor agonist ASC30, which is undergoing clinical trials for the treatment of type 2 diabetes and obesity [1][2][3] - The Phase II study for ASC30 in treating type 2 diabetes has commenced dosing the first batch of participants, with top-line data expected in Q3 2026 [1] - A recent Phase II study for ASC30 in treating obesity involved 125 participants and demonstrated statistically significant weight loss of 5.4%, 7.0%, and 7.7% for doses of 20mg, 40mg, and 60mg respectively, with a dose-dependent effect [2] Group 2 - ASC30 is the first and only small molecule GLP-1 receptor agonist in clinical research that can be administered both orally once daily and via subcutaneous injection monthly to quarterly [2] - The overall discontinuation rate due to adverse events in the obesity study was 4.8%, indicating a favorable safety profile [2] - The CEO of Ascletis Pharma highlighted the strategic expansion of ASC30's clinical development into the large diabetes treatment market, emphasizing the potential for ASC30 to offer a best-in-class oral therapy option [3]
歌礼制药-B(01672.HK)：口服小分子GLP-1R激动剂ASC30治疗糖尿病的13周美国II期研究完成首批受试者给药